<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702221</url>
  </required_header>
  <id_info>
    <org_study_id>PR002-CLN-pro008</org_study_id>
    <nct_id>NCT00702221</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension</brief_title>
  <official_title>A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Encorium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiotensin Therapeutic Vaccine (ATV), which contains the novel adjuvant, CoVaccine HT™ , is
      being developed for the treatment of high blood pressure (hypertension), a major risk factor
      for serious diseases such as heart attacks and strokes. Many patients with high blood
      pressure fail to take their medicines as prescribed because they generally feel well, which
      often results in poor control of the condition. As a result, it is estimated that about 70%
      patients with hypertension do not have their blood pressure adequately controlled despite
      advances in the treatment of high blood pressure.

      The main aim of this study is to find out if an injection of ATV given in the arm once every
      3 weeks on 3 occasions results in lowering overall blood pressure measurements throughout the
      day. The other aims are to find out if ATV is safe and to see how well it is tolerated
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the causes of hypertension is overactivity of the renin angiotensin system, the main
      mechanism by which the human body regulates its sodium and water balance. An enzyme called
      renin cleaves a peptide from the protein angiotensinogen, releasing angiotensin I (AI), which
      is then converted to a peptide hormone called angiotensin II (AII) by the angiotensin
      converting enzyme (ACE). Angiotensin II is a hormone which is a powerful vasoconstrictor and
      increases blood flow to vital organs. Angiotensin Therapeutic Vaccine acts by inducing
      antibodies which bind to angiotensin, so suppressing its actions.

      ATV may offer a way of improving control of blood pressure by increasing patient compliance
      with treatment. Infrequent vaccinations may provide a sustained reduction in blood pressure
      and afford a desirable, slow onset of action. Such a vaccine could provide an adjunct to and
      possibly a replacement for existing therapy in some patients, particularly where patient
      compliance is likely to be a problem.

      This study will determine if three injections of ATV given over the period of six weeks will
      reduce daytime BP as measured by ambulatory blood pressure monitoring.

      The study is split into 2 stages Stage A and Stage B.

      The rationale behind Stage A is to closely evaluate the safety and tolerability of ATV in a
      small number of subjects prior to enroling the majority of subjects into the remaining
      portion of the study. Stage A will include a minimum of 12 subjects who will receive each of
      their three injections at a dedicated Phase 1 facility with access to critical care
      facilities.

      Based on the safety profile of the stage A subjects, a recommendation will be made by an
      independent Data Safety Monitoring Committee on whether to proceed to Stage B.

      Stage B will include approximately 112 subjects. As safety and tolerability will have been
      closely assessed in Stage A, Stage B subjects will be monitored less closely and will be
      recruited from a number of sites in the UK.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Dose limiting adverse effects
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 8 in Mean Daytime Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>baseline to 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypertension</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>ATV with CoVaccine HT™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoVaccine HT™ adjuvant alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CoVaccine HT™ adjuvant alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant</intervention_name>
    <description>Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart</description>
    <arm_group_label>ATV with CoVaccine HT™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CoVaccine HT™ adjuvant</intervention_name>
    <description>Given as three separate intramuscular injections into the arm, 21 days apart</description>
    <arm_group_label>CoVaccine HT™ adjuvant alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (at randomisation):

          1. Competent to provide written informed consent

          2. 35-70 years old

          3. Body Mass Index (BMI) 19 to 33 kg/m2

          4. Mild to moderate hypertension per British Hypertension Society (BHS) Guidelines BHS-IV
             based on the following criteria of sitting blood pressure for subjects without
             diabetes or renal dysfunction.

          5. Average sitting morning DBP 90 to 109 mmHg and SBP 140 to 179 mmHg and have responded
             positively to a quinapril challenge.

        Principal exclusion criteria:

          1. Women of childbearing potential: defined to be not surgically sterile and &lt;2 y
             post-menopausal

          2. Average sitting SBP of &gt;180 mmHg or DBP of &gt;110 mmHg.

          3. A BP difference between left and right arm greater than 20 mmHg for SBP and 10 mmHg
             for DBP which is present on 3 consecutive readings.

          4. Left ventricular (LV) systolic dysfunction as evidenced by a known LV ejection
             fraction &lt;40% or symptomatic congestive heart failure requiring treatment.

          5. HbA1c &gt;7.0% or a history of Type 1 or Type 2 diabetes.

          6. Haemoglobin &lt;12 g/dL at Screening.

          7. Hypo- or hyperthyroidism

          8. Serum alanine aminotransferase or aspartate aminotransferase &gt;2X ULN.

          9. Other identifiable secondary causes of hypertension

         10. Myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within
             6 months of Screening.

         11. Bradycardia &lt;50 beats per minute at rest in the supine position prior to
             randomisation.

         12. Have sick sinus syndrome or second or third degree atrioventricular block, chronic
             atrial fibrillation or recurrent atrial tachyarrhythmia (including paroxysmal atrial
             tachycardia), history of recurrent ventricular tachycardia, or symptomatic
             bradycardia.

         13. Implanted pacemakers or cardioverter defibrillator.

         14. Haemodynamically significant valvular heart disease.

         15. History of renal dysfunction and/or estimated glomerular filtration rate &lt;60
             mL/min/1.73 m2.

         16. Diagnosis or recurrence of malignancy within the past 3 years, with the exception of
             basal cell carcinoma of the skin or in situ carcinoma of the cervix.

         17. Sleep apnea unless a recent (within 30 days of Screening) sleep study demonstrates no
             recordings of arterial oxygen saturation (SaO2) &lt;90%, treated or untreated, at any
             time during the Screening Period.

         18. Perform alternating shift or night work.

         19. Not on stable doses of all concomitant medications for a minimum of 4 weeks prior to
             Screening, and subjects treated with any of the following prohibited medications:

               -  Oral corticosteroids within 3 months of Screening.

               -  Acetylsalicylic acid in excess of 325 mg per day.

               -  Chronic stable or unstable use of non-steroidal anti-inflammatory drugs (NSAIDs)
                  other than acetylsalicylic acid is prohibited.

               -  Selective serotonin reuptake inhibitors or selective serotonin norepinephrine
                  reuptake inhibitors, if a subject is not compliant with the medication and/or has
                  not been receiving a stable dose for at least 3 months prior to Screening.

               -  Tricyclic antidepressants, if a subject is not compliant with the medication
                  and/or has not been receiving a stable dose for at least 3 months prior to
                  Screening.

               -  Any angiotensin vaccine, including prior exposure to ATV.

         20. Have participated in a clinical study involving another investigational drug or device
             within 4 weeks of Screening.

         21. Any concomitant condition that, in the opinion of the investigator, may adversely
             affect the safety and/or efficacy of the study drug or severely limit the subject's
             ability to complete the study (eg, disabling or terminal illness, mental disorders).

         22. Any major contraindication to stopping antihypertension medications for a period of up
             to 14 weeks.

         23. Previous exposure to CoVaccine HT adjuvant, or other keyhole limpet
             haemocyanin-containing vaccines.

         24. Previous serious reaction to a vaccine, such as angioedema or anaphylaxis.

         25. Known history of drug and/or alcohol abuse and those known to be hepatitis positive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wajdi H Turkie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Acumen Pharmaceuticals Services Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fowey River Practice</name>
      <address>
        <city>Fowey</city>
        <state>Cornwall</state>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alverton Practice</name>
      <address>
        <city>Penzance</city>
        <state>Cornwall</state>
        <zip>TR18 4JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saltash Health Centre</name>
      <address>
        <city>Saltash</city>
        <state>Cornwall</state>
        <zip>PL12 6DL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Cornwall Surgery</name>
      <address>
        <city>St. Just</city>
        <state>Cornwall</state>
        <zip>TR19 7HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brannel Surgery</name>
      <address>
        <city>St. Stephen</city>
        <state>Cornwall</state>
        <zip>PL26 7RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avondale Surgery</name>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>S40 4FT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knowle House Surgery</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL5 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Layton Medical Centre</name>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY3 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherbourne Medical Centre</name>
      <address>
        <city>Leamington Spa</city>
        <state>Warwickshire</state>
        <zip>CV32 4RA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbey Meads Medical Practice</name>
      <address>
        <city>Swindon</city>
        <state>Wiltshire</state>
        <zip>SN25 4YZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Gable Surgery</name>
      <address>
        <city>Inkberrow</city>
        <state>Worcestershire</state>
        <zip>WR7 4BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Acumen Pharmaceutical Services Ltd</name>
      <address>
        <city>Manchester</city>
        <zip>M50 2GY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <results_first_submitted>September 10, 2014</results_first_submitted>
  <results_first_submitted_qc>June 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2016</results_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high blood pressure</keyword>
  <keyword>vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Investigators provide information to participants</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Angiotensin Therapeutic Vaccine With CoVaccine HT™ Adjuvant</title>
          <description>Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant: Given as three separate intramuscular injections into the arm, 21 days apart</description>
        </group>
        <group group_id="P2">
          <title>CoVaccine HT™ Adjuvant Alone (Control)</title>
          <description>CoVaccine HT™ adjuvant alone
CoVaccine HT™ adjuvant: Given as three separate intramuscular injections into the arm, 21 days apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All analyzed subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Angiotensin Therapeutic Vaccine With CoVaccine HT™ Adjuvant</title>
          <description>Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant: Given as three separate intramuscular injections into the arm, 21 days apart</description>
        </group>
        <group group_id="B2">
          <title>CoVaccine HT™ Adjuvant Alone (Control)</title>
          <description>CoVaccine HT™ adjuvant alone
CoVaccine HT™ adjuvant: Given as three separate intramuscular injections into the arm, 21 days apart</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="6.94"/>
                    <measurement group_id="B2" value="53.7" spread="6.63"/>
                    <measurement group_id="B3" value="52.8" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 8 in Mean Daytime Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)</title>
        <time_frame>baseline to 8 weeks</time_frame>
        <population>study prematurely terminated</population>
        <group_list>
          <group group_id="O1">
            <title>Angiotensin Therapeutic Vaccine + CoVaccine HT™ Adjuvant</title>
            <description>Angiotensin Therapeutic Vaccine + CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
Angiotensin Therapeutic Vaccine + CoVaccine HT™ adjuvant: Given as three separate intramuscular injections into the arm, 21 days apart</description>
          </group>
          <group group_id="O2">
            <title>CoVaccine HT™ Adjuvant Alone (Control)</title>
            <description>CoVaccine HT™ adjuvant alone
CoVaccine HT™ adjuvant: Given as three separate intramuscular injections into the arm, 21 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean Daytime Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)</title>
          <population>study prematurely terminated</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.18" spread="3.451"/>
                    <measurement group_id="O2" value="-3.68" spread="3.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Angiotensin Therapeutic Vaccine With CoVaccine HT™ Adjuvant</title>
          <description>Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant: Given as three separate intramuscular injections into the arm, 21 days apart</description>
        </group>
        <group group_id="E2">
          <title>CoVaccine HT™ Adjuvant Alone (Control)</title>
          <description>CoVaccine HT™ adjuvant alone
CoVaccine HT™ adjuvant: Given as three separate intramuscular injections into the arm, 21 days apart</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hyperesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study prematurely terminated</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>SVP, Clinical Development</name_or_title>
      <organization>BTG International Inc.</organization>
      <phone>610-278-1660</phone>
      <email>thomas.king@btgplc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

